| Literature DB >> 28336808 |
Stuart W Ember1, Que T Lambert2, Norbert Berndt1, Steven Gunawan1, Muhammad Ayaz3, Marilena Tauro4, Jin-Yi Zhu1, Paula J Cranfill1, Patricia Greninger4, Conor C Lynch5, Cyril H Benes4, Harshani R Lawrence1,3, Gary W Reuther2, Nicholas J Lawrence6, Ernst Schönbrunn6.
Abstract
Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers. Using the chemical scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1. Lead compounds showed on-target inhibition in several blood cancer cell lines and were highly efficacious at inhibiting the growth of hematopoietic progenitor cells from patients with myeloproliferative neoplasm. Screening across 931 cancer cell lines revealed differential growth inhibitory potential with highest activity against bone and blood cancers and greatly enhanced activity over the single BET inhibitor JQ1. Gene drug sensitivity analyses and drug combination studies indicate synergism of BRD4 and kinase inhibition as a plausible reason for the superior potency in cell killing. Combined, our findings indicate promising potential of these agents as novel chemical probes and cancer therapeutics. Mol Cancer Ther; 16(6); 1054-67. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28336808 PMCID： PMC5457702 DOI： 10.1158/1535-7163.MCT-16-0568-T
Source DB: PubMed Journal: Mol Cancer Ther ISSN： 1535-7163 Impact factor: 6.261